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The transformational impact of CAR T cell therapies on serious diseases demands a rapid path to licensure in 
order to establish widespread availability to desperate patients.  In addition, the complex, labor intensive, and 
costly patient-specific manufacturing processes for CAR T cell therapies demand process modifications that 
enable scalability and affordability to maximize availability to patients.  There are many options to improve CAR 
T processes ranging from automation to improved medium composition to simplified closed-system tubing sets.  
However, the dramatic dose-dependent safety and efficacy activities of these therapies amplifies the need for 
maintaining product comparability across process changes.  This assessment of comparability is challenged by 
limited knowledge of product Critical Quality Attributes as well as limited availability of patient cells for process 
development studies.  We have developed a comprehensive analytical toolbox that enables the assessment of 
product impact of process changes along with a risk-based approach to applying a matrix of appropriate tools 
for each change.  This risk-based approach involves the most extensive product analysis for high-risk changes 
and a relatively restricted product analysis for low-risk changes.  In all cases, the product analysis includes 
assessments of product characteristics that can hypothetically be impacted by the process change.  We 
describe our approach to identifying, prioritizing, and assessing feasibility of process changes along with 
generating a suitable product comparability dataset to implement the most impactful process changes on an 
expedited timeline to licensure.  We share examples of comparability data and its application to decision 
making.   
 
